Ironwood Pharmaceuticals Inc. (Class A) (IRWD) carries a Roarable Rating of C- (Hold) with 59/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.
As of 2026-11-03, Ironwood Pharmaceuticals Inc. (Class A) (NASDAQ: IRWD) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 59/100 at a spot price of $3.50 (-3.31% 1D, market cap $578.3M). Pillar breakdown: Fundamental Cash Engine 15/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 12/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 17/20. Across 1016 tracked Health Care issuers, IRWD ranks #171 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), IRWD carries a Roarable C- (59/100 RQD), trailing P/E of 24.9x, gross margin of —, and ROIC of 85.0%. By comparison, GERN (Geron Corporation) holds a E grade (28/100 RQD, P/E N/A, ROIC -20.2%, cap $574.6M) and ACRS (Aclaris Therapeutics Inc.) posts a E grade (19/100 RQD, P/E N/A, ROIC -35.0%, cap $584.4M). Among the 5-stock peer group, IRWD leads on earnings multiple (24.9x) while IRWD leads on capital efficiency (85.0% ROIC).
Per IRWD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001446847), Ironwood Pharmaceuticals Inc. (Class A) generated $296.2M in revenue (-15.7% YoY), $24.0M in net income, and $127.0M in free cash flow against $396.9M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
SEC Form 4 / 13F Thermometer: 85% Net Buy • Cannibal Buyback (-2.64% YoY Shares)
SEC XBRL FY 2025 (10-K): 42.9% FCF Margin ($127.0M FCF) & 52% Gross Margin
Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)
Even with a 59/100 (C-) score, IRWD faces multiple-compression risk if 24.9x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
Dilution & Margin Drag: Cannibal Buyback (-2.64% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($3.93) or 200D SMA ($3.98) invalidates the momentum regime and cuts Target Base ($3.52) toward Bear Floor ($2.75).
Ironwood Pharmaceuticals Inc. (Class A) (IRWD) dropped -3.31% to $3.50, trading at 43% of its 52-week range ($1.76 – $5.78). Solid steady margins (85% return on capital), mixed timing at 25x P/E—hold if owned, no rush to chase.
Seeking Alpha report covering Ironwood Pharmaceuticals Inc. (Class A) (IRWD) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering Ironwood Pharmaceuticals Inc. (Class A) (IRWD) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Ironwood Pharmaceuticals Inc. (Class A) (IRWD) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Ironwood Pharmaceuticals Inc. (Class A) (IRWD) market action, institutional positioning, and fundamental catalysts.
ad-hoc-news.de report covering Ironwood Pharmaceuticals Inc. (Class A) (IRWD) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering Ironwood Pharmaceuticals Inc. (Class A) (IRWD) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering Ironwood Pharmaceuticals Inc. (Class A) (IRWD) market action, institutional positioning, and fundamental catalysts.
BOSTON, October 28, 2026--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), today announced it will host its third quarter 2026 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, November 5,
BOSTON, October 16, 2026--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, toda
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today announced that its
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -15.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on IRWD today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for IRWD. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Ironwood Pharmaceuticals Inc. (Class A) (IRWD) ranks #171 by composite RQD confidence (59/100, grade C-) and #420 by equity capitalization ($578.3M). Within this direct 5-issuer industry benchmark cohort, IRWD leads on earnings valuation at 24.9x trailing P/E, while IRWD leads on capital efficiency and profitability with 85.0% ROIC and — gross margin. IRWD currently leads its immediate peer cohort in composite quantitative strength at 59/100 (C-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| IRWD
ACTIVE
Ironwood Pharmaceuticals Inc. (Class A) | C- | 59/100 | 24.9x | — | 85.0% | -3.31% | $578.3M | Benchmark Subject |
| GERN Geron Corporation | E | 28/100 | — | — | -20.2% | -5.47% | $574.6M | /gern-vs-irwd → |
| ACRS Aclaris Therapeutics Inc. | E | 19/100 | — | 73.3% | -35.0% | -0.50% | $584.4M | /acrs-vs-irwd → |
| CLYM Climb Bio Inc. | E | 28/100 | — | — | -35.0% | -0.77% | $588.7M | /clym-vs-irwd → |
| STTK Shattuck Labs Inc. | E | 29/100 | — | — | -35.0% | -2.80% | $558.0M | /sttk-vs-irwd → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Ironwood Pharmaceuticals Inc. (Class A) (IRWD) reported GAAP revenue of $296.2M (-15.7% vs. FY2024 revenue of $351.4M , and -33.1% cumulative change since FY2023) , GAAP net income of $24.0M, operating cash flow of $127.0M, and free cash flow of $127.0M (+22.8% YoY). On the balance sheet, IRWD closed FY2025 with $396.9M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 7/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $296.2M | $24.0M | $127.0M | $127.0M | $396.9M | — |
| FY2024 (FY) | 2024-12-31 | $351.4M | $880.0K | $103.5M | $103.4M | $350.9M | — |
| FY2023 (FY) | 2023-12-31 | $442.7M | -$1.03B | $183.4M | $183.4M | — | — |
As of 2026-11-03, Ironwood Pharmaceuticals Inc. (Class A) (NASDAQ: IRWD) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 59/100 at a spot price of $3.50 (-3.31% 1D, market cap $578.3M). Pillar breakdown: Fundamental Cash Engine 15/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 12/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 17/20. Across 1016 tracked Health Care issuers, IRWD ranks #171 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), IRWD carries a Roarable C- (59/100 RQD), trailing P/E of 24.9x, gross margin of —, and ROIC of 85.0%. By comparison, GERN (Geron Corporation) holds a E grade (28/100 RQD, P/E N/A, ROIC -20.2%, cap $574.6M) and ACRS (Aclaris Therapeutics Inc.) posts a E grade (19/100 RQD, P/E N/A, ROIC -35.0%, cap $584.4M). Among the 5-stock peer group, IRWD leads on earnings multiple (24.9x) while IRWD leads on capital efficiency (85.0% ROIC).
Per IRWD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001446847), Ironwood Pharmaceuticals Inc. (Class A) generated $296.2M in revenue (-15.7% YoY), $24.0M in net income, and $127.0M in free cash flow against $396.9M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.. Institutional options positioning shows a 50% call / 50% put premium split.
IRWD last traded at $3.50 (-3.31% on volume of 1,470,631 shares), positioning the stock -10.94% below its 50-day simple moving average ($3.93) and -12.06% below its 200-day simple moving average ($3.98). Across its 52-week range of $1.76 to $5.78, IRWD sits at the 43.3% percentile with a 14-day RSI of 41.9 (NEUTRAL RANGE) and an implied next-earnings move of ±9.9% ($3.15 to $3.85).
Why IRWD Stock dropped -3.31% Today — RQD Quant Desk Flash. Solid steady margins (85% return on capital), mixed timing at 25x P/E—hold if owned, no rush to chase.
Per the Roarable RQD rating, IRWD scores 63 out of 100, a letter grade of C, with the verdict label "Roarable Hold — Fair / Balanced Risk-Reward." The five pillars are:
For a prospective investor, the rating describes a mixed picture: exceptional reported cash-return metrics and strong insider-flow scoring are weighed against weak institutional flow and a low Altman Z-Score. The valuation tradeoff is visible in the market data: trailing P/E of 24.9 and forward P/E of 23.2 sit alongside an EV/EBITDA of 3.9, so the multiple picture depends heavily on which earnings measure is emphasized. The rating's "Hold" verdict reflects this balance rather than a directional call. This is an analytical framing, not personalized advice.
Ironwood Pharmaceuticals Inc. (Class A) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry. Per the company profile, it has a market capitalization of $0.6B. The source data does not describe its products, customers, or specific revenue model.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $296.2M | $98.5M | $24.0M | N/A | $127.0M | $215.5M | N/A |
| FY 2024 | $351.4M | $93.1M | $0.9M | N/A | $103.4M | $88.6M | N/A |
| FY 2023 | $442.7M | $-945.4M | $-1031.6M | N/A | $183.4M | N/A | N/A |
Per the SEC financials, revenue declined from $442.7M in FY 2023 to $351.4M in FY 2024 and $296.2M in FY 2025, while operating income turned positive in FY 2024 and remained positive at $98.5M in FY 2025. Per the market data, operating margin is 33.3% and net margin is 8.1%, with ROIC at 85%. Per the Roarable RQD rating, the Altman Z-Score is 0.2 and the Piotroski F-Score is 7/9, a combination that pairs a weak distress-model reading with a relatively strong accounting-quality reading. Per the Roarable RQD rating, Debt/Equity is 0.5.
Real-time company headlines, analyst actions, and sector developments for Ironwood Pharmaceuticals Inc. (Class A) (IRWD) • Click "Debate This Headline" to argue it in the Roar Pit below
Seeking Alpha report covering Ironwood Pharmaceuticals Inc. (Class A) (IRWD) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering Ironwood Pharmaceuticals Inc. (Class A) (IRWD) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Ironwood Pharmaceuticals Inc. (Class A) (IRWD) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Ironwood Pharmaceuticals Inc. (Class A) (IRWD) market action, institutional positioning, and fundamental catalysts.
ad-hoc-news.de report covering Ironwood Pharmaceuticals Inc. (Class A) (IRWD) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering Ironwood Pharmaceuticals Inc. (Class A) (IRWD) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering Ironwood Pharmaceuticals Inc. (Class A) (IRWD) market action, institutional positioning, and fundamental catalysts.
BOSTON, October 28, 2026--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), today announced it will host its third quarter 2026 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, November 5,
Welcome to the IRWD (Ironwood Pharmaceuticals Inc. (Class A)) Roar Pit. Current RQD Composite is 63/100 (Roarable Hold — Fair / Balanced Risk-Reward) in Biotechnology: Pharmaceutical Preparations. Bulls point to capital efficiency (85.0% ROIC), while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on IRWD, but look at what you are paying: 24.9x trailing P/E with tightening sector spreads. Unless Ironwood Pharmaceuticals Inc. (Class A) expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on IRWD, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $3.62 (52-wk range $1.61 - $5.78), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).